Navigation Links
CWRU dental researcher's NIDCR grant targets oral bacteria and fetal death link
Date:7/8/2013

A new four-year, $1.58 million grant from the National Institute of Dental and Craniofacial Research, will allow a Case Western Reserve University School of Dental Medicine researcher to advance her work linking oral bacteria to fetal death.

The grant will support a study by Yiping Han, professor of periodontics that focuses on the prevalent oral bacteria, Fusobacterium, and several of its subspecies. The bacteria keeps the mouth's natural disease defenses working, but can also cause diseases when they enter the bloodstream and travel throughout the body, including the placenta, umbilical cord and fetus.

In prior research, Han has linked the bacteria to stillbirth, post-birth sepsis and premature births due to inflammation in the placenta, which is supposed to be bacteria-free.

Of Fusobacterium's five subspecies, two have mechanisms that allow them to leave the mouth and travel to other parts of the body, including the placenta.

"We are interested in why more of some subspecies are found in the uterus and placenta, but others never leave the mouth," Han said. "We have to find out why, and then stop them."

Until they have an answer, Han urges everyonenot just pregnant womento maintain their oral health.

In another recent study, Han and Xiaowei Wang, postdoctoral scholar in Han's lab, found that atherosclerotic disease, adverse pregnancy outcomes, rheumatoid arthritis, inflammatory bowel disease, colorectal cancer and respiratory tract infections all had oral bacteria connections.

"Almost every disease in research literature reviewed has the presence of Fusobacterium at the diseased site," Han concluded in the study.

About 700 species of bacteria live in the mouth, according to Han. Some will never leave that environment. But others, like Fusobacterium, have developed the ability to slip between cells in blood vessel walls to enter the blood and establish "colonies
'/>"/>

Contact: Susan Griffith
susan.griffith@case.edu
216-368-1004
Case Western Reserve University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Surge in children accidentally eating marijuana-laced foods
2. Accidental discovery may lead to improved polymers
3. ACMG releases report on incidental findings in clinical exome and genome sequencing
4. Measuring mercury: Common test may overestimate exposure from dental amalgam fillings
5. 2 Cell Transplantation studies impact dental stem cell research for therapeutic purposes
6. Dental X-rays linked to common brain tumor
7. UCLA researchers find new clue to cause of human narcolepsy
8. Researchers discover new way to block inflammation
9. Researchers call for rethinking efforts to prevent interplanetary contamination
10. Northwestern researchers examine mechanical bases for the emergence of undulatory swimmers
11. Researchers determine factors that influence spinach contamination pre-harvest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... on different species of fish, according to a ... Exeter which tested fish anti-predator behaviour. , ... predator model when exposed to additional noise, whereas ... , Lead author Dr Irene Voellmy of Bristol,s ... many aquatic environments have increased substantially during the ...
(Date:7/24/2014)... its own microbial terroir, meaning the microbial populations found ... the product, creating the final flavor according to research ... and Environmental Microbiology . This is the first time ... brewery. , Many sake makers inoculate with both ... of the University of California, Davis, but he and ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4The microbes make the sake brewery 2
... 2010) -- Drug delivery inside the body is a ... solutions, lipid membranes, and barriers between the blood and ... Institute of Physics publication the Journal of Chemical ... the hydration free energy (HFE) of a wide variety ...
... (July 27, 2010) -- In biology and genetics, the concept ... more (or less) than the sum of its parts. The ... an organism has the potential to depend strongly upon the ... even other mutations co-occurring in that gene. These genetic interactions, ...
... punch tiny holes in the protective membranes of cells, ... small molecules, proteins and DNA directly into living cells. ... light trigger the tiny blasts, which open holes in ... contained in the surrounding fluid. By adjusting laser ...
Cached Biology News:Getting a step ahead of pathogens 2Nanoblasts from laser-activated nanoparticles move molecules, proteins and DNA into cells 2Nanoblasts from laser-activated nanoparticles move molecules, proteins and DNA into cells 3Nanoblasts from laser-activated nanoparticles move molecules, proteins and DNA into cells 4
(Date:7/24/2014)... Calif. , July 24, 2014 SRI ... contract with the National Institute of Allergy and Infectious ... to conduct preclinical development of potential therapies for HIV ... drugs to treat HIV and AIDS and the complications ... as microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... 24, 2014 WIRB-Copernicus Group ® ... ethical review services for clinical research, announced today ... division of Richmond, VA -based ... and biosecurity consulting firm in the ... biosafety division – WCG Biosafety™ – will be ...
(Date:7/24/2014)... 24, 2014   Cypher Genomics, Inc., ... of Adam Simpson as president and ... and comprehensive annotation and interpretation of individual human ... "Cypher,s technology has the potential to play ... diagnostic accuracy, optimizing therapeutic approaches and reducing adverse ...
(Date:7/23/2014)... Inc. (NASDAQ: SGMO ) today reported its ... For the second quarter ended June 30, 2014, ... or $0.10 per share, compared to a net loss ... same period in 2013. As of June 30, 2014, ... interest receivable of $236.7 million. Revenues for ...
Breaking Biology Technology:National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9
... Submission for Removal of Clinical Hold, BERKELEY ... Board: GNTA) announced that the Company has,received notice ... European,Patent Office for its pipeline product, tesetaxel, a ... matter for the tesetaxel drug,substance and to processes ...
... prion reduction technology to, further reduce risk of variant ... ... Octaplas(R), - Octapharma sponsoring lunchtime Symposium at meeting to discuss ... product quality., MONTREAL, Canada and CAMBRIDGE, United Kingdom, June 10,/PRNewswire-FirstCall/ ...
... Targets, COPENHAGEN, June 10 Nuevolution A/S ... (Nasdaq: LXRX ) aimed,at the discovery of ... targets., Under the terms of the alliance, ... to identify novel small molecule,lead compounds against a ...
Cached Biology Technology:Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane 2Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane 3Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane 4ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 2ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 3ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 4ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 5ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 6Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals 2Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals 3
Mouse monoclonal [SPM217] to Secretory Component Glycoprotein ( Abpromise for all tested applications)....
Rabbit polyclonal to FLIP ( Abpromise for all tested applications). entrezGeneID: 8837 SwissProtID: O15519...
... [EP282Y] to Asparagine synthetase ( ... applications). Antigen: ... residues in the C-terminus of ... Entrez GeneID: 440 ...
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 25 tests...
Biology Products: